Home » Newsletters » BioWorld Science

BioWorld Science

April 12, 2019

View Archived Issues

Tetraphase Pharmaceuticals presents TP-2846 for leukemia therapy

TAK-169 shows promising activity in models of CD38-expressing multiple myeloma

Highly selective PIKdelta inhibitor IOA-244 has preclinical efficacy in cancer models

M-4076 enhances the efficacy of radiotherapy in preclinical models

Initiation of phase I/II study of OTO-313 in patients with tinnitus

Pragma Therapeutics discovers mGlu7 receptor antagonists

New Janus kinase inhibitors described by Beijing Scitech-Mq Pharmaceuticals

Takeda discovers hypoxia-inducible factor prolyl hydroxylase inhibitors

Channel Therapeutics identifies P. aeruginosa transcriptional activator protein LasR inhibitors

Patient enrollment ongoing in phase I NeoPepVac study

Lead Discovery Center and collaborators patent coumarin derivatives

Orbsen initiates treatment in MERLIN study of its second-generation immunotherapy ORBCEL-C

Rubius Therapeutics reports new allogeneic RBCs for treating solid tumors

Mallinckrodt, Washington University to jointly search for drugs targeting chronic itch

University of Louisville and Qualigen to develop RAS inhibitor candidates

GlaxoSmithKline enrolling in first-in-human study of GSK-3745417 for advanced solid tumors

Evotec and Exscientia detail discovery of EVOEXS-21546 for cancer immunotherapy

FDA approves expanded monotherapy label for Keytruda in first-line NSCLC

Autophagy disruption affects social behavior in mice

TATTON study results reported for osimertinib with selumetinib or savolitinib in EGFR-mutant NSCLC

Tracon terminates for futility phase III TAPPAS trial of TRC-105 in angiosarcoma

AUT-00206 reduces ketamine-induced BOLD response in phase Ib study

Sernova conducts first Cell Pouch transplant in U.S. phase I/II trial for type 1 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...